ipilimumab,nivolumab,durvalumab,paclitaxel,vinorelbine,carboplatin,cisplatin,gemcitabine,docetaxel,pemetrexed
bms,astrazeneca
['aegean', 'cm816']
#aacr23 #aegean 3yr 63% efs data presented comparable to #cm816 with cpr (17%) you shouldn t do cross-trial comparisons but we can t help ourselves and wonder: is all the benefit of io seen upfront in the neoadj setting? looking forward to more data to answer this 
Associate Director Community Outreach- DEI- 🫁Thoracic Oncology, University of Miami @SylvesterCancer , 🇵🇷Boricua, Co-founder @KidsHelpingKidsSucceed